Eva Ellebaek - Publications

Immune-cytokine signature predicts survival in patients with advanced melanoma treated with oncolytic adenovirus TILT-123 and chemotherapy and IL-2-free adoptive TIL therapy.

Journal: Journal for immunotherapy of cancer

Published: July 27, 2026

Corrigendum to "Discontinuation of BRAF/MEK inhibitor therapy after long-lasting response: Clinical outcomes in advanced melanoma" [Eur J Cancer 234 (2026) 116200].

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 21, 2026

Sentinel node biopsy and survival in cutaneous melanoma: a nationwide population-based cohort study.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: May 21, 2026

Prognostic dynamics of pathological complete response and ctDNA clearance after neoadjuvant/perioperative immunotherapy in cancer: a reconstructed individual patient analysis.

Journal: Journal of the National Cancer Institute

Published: April 09, 2026

Progression risk among responders to PD-1/PD-L1 blockade is primarily stratified by response depth: A nationwide cohort study of 2127 patients with melanoma, RCC, and NSCLC.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 22, 2026

Five-year survival impact of adjuvant anti-PD-1 therapy in a nationwide cohort of stage III melanoma.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: March 19, 2026

Quantifying the efficacy-effectiveness gap in first line treatment of metastatic melanoma.

Journal: Journal of the National Cancer Institute

Published: March 09, 2026

Prospective study of patients with immune checkpoint inhibitor-induced hepatitis; characterization of liver injury, outcome of therapy, and management of steroid-unresponsive and steroid-dependent hepatitis.

Journal: Journal for immunotherapy of cancer

Published: February 09, 2026

Real-World Outcomes of Nivolumab and Ipilimumab in Metastatic Melanoma as Third Line and Beyond.

Journal: International journal of cancer

Published: January 28, 2026

Corrigendum to "Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028": [ESMO Open 10 (2025) 104295].

Journal: ESMO open

Published: January 03, 2026

Impact of adjuvant anti-PD-1 immunotherapy on ovarian function in female patients with resectable melanoma: A prospective observational study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: November 24, 2025

Discontinuation of BRAF/MEK inhibitor therapy after long-lasting response: Clinical outcomes in advanced melanoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 23, 2025